𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

✍ Scribed by Giles, F J; le Coutre, P D; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottmann, O G; Hochhaus, A; Radich, J P; Saglio, G; Hughes, T P; Martinelli, G; Kim, D-W; Novick, S; Gillis, K; Fan, X; Cortes, J; Baccarani, M; Kantarjian, H M

Book ID
118231749
Publisher
Nature Publishing Group
Year
2012
Tongue
English
Weight
383 KB
Volume
27
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Expanding Nilotinib Access in Clinical T
Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 213 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH